Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Advanced Biomed Inc. ( (ADVB) ).
On September 19, 2025, Advanced Biomed Inc. announced the launch of A+PerfusC™, an integrated perfusion 3D cell culture platform designed for precision medicine and drug discovery. This system replicates human physiological conditions in vitro, supporting continuous culture and enhancing cell viability and drug response predictability. The platform’s potential applications include personalized oncology research, drug screening, and regenerative medicine. The company plans to scale up the system for high-throughput use and integrate AI-driven analytics, aiming to accelerate tumor profiling and advance personalized treatment development.
More about Advanced Biomed Inc.
Advanced Biomed Inc. is a Nevada-incorporated holding company specializing in innovative biomedical technologies for cancer detection and precision medicine. Operating through subsidiaries in Taiwan, Hong Kong, and Mainland China, the company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell detection, enrichment, and analysis. Its portfolio includes devices and biochips designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in China and plans for future global expansion.
Average Trading Volume: 941,019
Technical Sentiment Signal: Strong Sell
See more insights into ADVB stock on TipRanks’ Stock Analysis page.